PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study - ScienceDirect

End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration - ScienceDirect

End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration - ScienceDirect

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study, Health and Quality of Life Outcomes

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

The Lens: Ophthalmology Research Newsletter on X: Check out our overview of the 2005 #MARINA study, for this week's #LensLandmarks! 👁️ The MARINA trial sought to determine the treatability of neovascular age-related

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry